Introduction
Systemic lupus erythematosus (SLE) is an incurable chronic disease that mostly affects young women of childbearing age. Clinical complaints include fatigue, joint and muscle pain, skin manifestations (rash) and headaches. Frequent laboratory abnormalities include positive antinuclear antibodies (ANA), the reduction of circulating neutrophils, lymphocytes, thrombocytes and complement components, and the presence of interferons, especially interferon-alpha (IFN-a) ( Figure 1 ). 1 While most of the initial clinical and laboratory features are non-specific and similar to non-selflimiting flu symptoms, highly specific findings are necessary to verify the diagnosis. These highly specific features can be identified either histologically (biopsies of inflamed kidney and skin) or by autoantibody testing. Autoantibodies against doublestranded DNA and the Smith (Sm) antigen are well-known hallmarks of SLE, but other autoantibodies such as those directed against nucleosomes, ribosomal P proteins and C1q are also considered diagnostic markers for SLE. Numerous other autoantibodies directed, for example, against phospholipids, surface molecules of blood cells and complement components, may also occur in SLE and, thus, contribute to the pathogenesis and clinical features of the disease. 2 
Definition and suitability of biomarkers in SLE
A biomarker is defined as a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention'. 3 Biomarkers for SLE should be subclassified according to their primary suitability to identify or predict a given: (a) diagnosis, (b) disease activity, (c) outcome (e.g. organ damage, mortality or response to treatment) or (d) disease manifestation (e.g. lupus nephritis).
Molecular biomarkers are thought to hold the key to developing personalized, patient-tailored medicine. Here, we provide an overview of biomarkers that can be used for such an approach in SLE. Since therapy for active SLE patients should be adjusted, a differential treatment approach based on biomarkers for SLE activity is needed.
Need for biomarkers in SLE
Assessment of lupus activity is often easy in young lupus patients who have only had the disease for a short duration, because most of their complaints are due to SLE. However, in lupus patients with cumulative damage or multiple comorbidities or medications (and potential side effects), it can be extremely difficult to differentiate between lupus activity and non-lupus-related complaints, even for very experienced lupus specialists. Validated biomarkers providing clear clinical information are extremely valuable in these cases. Clearly, the clinical benefit of a biomarker differs not only between patients but also between physicians, depending on their expertise in lupus and in interpreting biomarker tests.
Differential treatment and companion diagnostics
There are several important factors that determine lupus treatment decision-making. These include organ manifestations, the degree of disease activity, the presence or absence of comorbidities, previous treatments and the desire to have children. Nevertheless, biomarkers can also be used to guide and monitor therapy.
Diagnostic tests using biomarkers that identify patients who will benefit from a specific therapeutic agent are called companion diagnostics. Up to now, only low complement C3 and increased anti-dsDNA antibodies have been used as companion diagnostics in SLE patients treated with belimumab, an approved anti-BlyS/BAFF antibody. 4 The ability of the whole blood interferon signature to select and monitor SLE patients treated with inhibitors of type-I interferon has also been investigated in clinical trials. [5] [6] [7] Companion diagnostics are only one component of personalized medicine. Transcriptomics, proteomics and genomics, including epigenomics, provide a huge pool of potential biomarkers for personalized medicine approaches to SLE therapy in the future. Here, we will focus on applications involving autoantibodies, complement and type-I interferon.
Autoantibodies
First discovered by Holborow et al., ANA have been known for nearly 60 years. 8 Similar to complement components, autoantibodies -especially those against dsDNA -have been used to diagnose and assess SLE activity for more than 50 years. 9 Indirect immunofluorescence (IIF) tests for ANA screening on HEp-2 cells, ELISAs and other high throughput immunoassays for differentiation of ANA and detection of autoantibodies that typically occur in SLE, as well as the Crithidia luciliae immunofluorescence test (CLIFT), a highly specific assay for anti-dsDNA antibody detection, are standard diagnostic tests that are now available world-wide. Conversely, the highly sensitive and specific Farr assay for determination of anti-dsDNA antibodies is rarely used because it requires 125 I-labeled dsDNA.
In SLE, major T and B cell immune responses are directed against nucleosomes that are composed primarily of DNA and histone proteins. 10 Purified dsDNA is rarely found in nature, and is an in vitro construct, while in vivo dsDNA is always bound to histone proteins. Thus, anti-dsDNA antibodies belong to the family of anti-nucleosome antibodies (ANuA). 11
Diagnostic utility
Autoantibodies with a very high diagnostic specificity are useful for the diagnosis of SLE. However, because many test systems used in routine clinical practice lack independent validation, exact test criteria are not known. The specificity of an autoantibody test result generally increases with the magnitude of the measured value, but nowadays laboratories do not provide clinicians with the calculated specificity of a test result. This is of relevance, since anti-dsDNA-antibodies can be induced by many drugs. 12, 13 The most commonly used marker autoantibodies in SLE react with dsDNA, Smith (Sm) antigen, nucleosomes and ribosomal P proteins. 14, 15 Antinucleosome antibodies occur in SLE at a frequency of 60%-100 %. 16 The frequency range may be influenced by factors like ethnicity, disease duration, disease activity and treatment.
First-generation anti-nucleosome ELISAs were characterized by the use of nucleosomes that included the linker protein histone H1 and also traces of Scl70 (topoisomerase I). These assays produced false-positive results in patients with systemic sclerosis. 10 Second-generation anti-nucleosome ELISAs utilized chromatin chemically stripped of H1 and other loosely bound proteins like Scl-70 and, therefore, achieved superior diagnostic performance in SLE. 17 Interestingly, ELISAs using the strong adhesive property of nucleosomes (instead of commonly used linkers like methylated albumin, protamine sulfate or poly-L-lysine) to attach dsDNA to the plate, showed even higher diagnostic performance in SLE, and outperformed even the Farr assay. 14 
Clinical associations
The highest levels of autoantibodies are found in untreated young patients at the time of diagnosis, and in patients with renal involvement or with extremely high disease activity. Antibodies against dsDNA, Sm and C1q are strongly associated with lupus nephritis. 18, 19 In clinical practice, anti-C1q antibodies might be helpful, since a negative anti-C1q antibody test can exclude active renal involvement. 20, 21 Lupus hepatitis has been linked with anti-ribosomal P antibodies. 22, 23 When neuropsychiatric SLE is an issue, antibodies against phospholipids 24 and ribosomal P 25 should be checked. Neuromyelitis optica, a rare manifestation in SLE patients, is linked to autoantibodies directed against aquaporin 4, the most abundant water channel in the central nervous system (CNS). 26, 27 Disease activity
ANuA and anti-dsDNA antibodies are used as biomarkers for lupus disease activity. 16 In comparison to complement and interferon biomarkers, they are more specific for symptoms due to SLE. Anti-dsDNA antibodies are a component of the SLE disease activity index (SLEDAI). 28 Most studies investigating correlations between anti-dsDNA antibodies and disease activity use the SLEDAI. To avoid bias, the anti-dsDNA antibody item is excluded from some studies. Cross-sectional analysis reveals a weak but significant correlation between anti-dsDNA antibodies and SLE activity. Increased levels of anti-dsDNA antibodies have been found in 15% of patients with inactive SLE patients compared to 44% of those with moderate to severe disease active. In comparison, ANuA are elevated in 23% of inactive and in 63% of highly active SLE patients. 29 Regarding the correlation of anti-dsDNA antibodies with disease activity over time, contradictory reports have been published in the literature. The published findings range from a positive correlation 30 to no correlation 31 to a negative correlation. 32 Our longitudinal prospective cohort study showed a very weak but significant correlation between anti-dsDNA levels (ELISA) and disease activity (Rose et al., unpublished) . Nevertheless, when we used a benchmark analysis based on longitudinal upper and lower thresholds, anti-dsDNA antibodies indicated 66% of flares and 75% of remissions. In the same benchmark analysis, ANuA predicted 70% of flares and 100% of remissions. All in all, ANuA might be the better choice for longitudinal monitoring of SLE patients, as was also reflected in a review by Bizzaro and colleagues. 16 
Prognostic utility
Autoantibody markers for SLE are detectable several years before clinical onset. 33 Significant increases in anti-dsDNA antibodies have been described before the time of diagnosis and before flares. 29, 30, 33 Inactive SLE patients with elevated anti-dsDNA levels have more frequent flares than their anti-dsDNA-negative counterparts. The same holds true for ANuA. 34 Bootsma et al. used the outdated Farr assay to monitor 156 clinically inactive SLE patients monthly for a rise in anti-dsDNA compared to their previous anti-dsDNA level. 35 Such a rise did occur in 46 patients, who were then treated in double-blinded fashion with either placebo or a higher dose of prednisolone. Relapses occurred at a significantly lower rate in the higher-dose prednisolone group, although the cumulative doses of prednisolone did not differ significantly between the two treatment arms. About 10 years later, Tseng et al. reported comparable results using ELISA in a similar study, in which 154 patients were evaluated at monthly intervals for up to 18 months. In addition to a 25% increase in the anti-dsDNA level measured, 50% elevation of the C3a level over the previous 1-2 months was needed to randomize these patients to receive either a higher dose of prednisolone or placebo. The higher dose of prednisolone significantly reduced the occurrence of severe flares. The number needed to treat in order to prevent one severe flare was 3.33 patients. 36 
Companion diagnostics
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to treatment, especially to drugs that target autoantibody production. 4, 37 Plasmablasts and plasma cells
Autoantibodies are generated and secreted by two different plasma cell populations, which exist independently of each other. One population consists of newly generated short-lived plasmablasts (SLPBs) and plasma cells reflecting B cell hyperactivity. The second is located mainly in the bone marrow, but also in inflamed tissues, where plasma cells become long-lived and thus provide humoral memory. SLPBs and plasma cells respond to glucocorticoids, conventional immunosuppressive drugs and therapies targeting B cells, whereas long-lived memory plasma cells are refractory to these treatments. Therefore, autoantibodies that persist despite immunosuppressive drugs or B cell targeted therapies can be assumed to be produced by long-lived memory plasma cells. 38 The expansion of SLPBs in the circulation can be detected using flow cytometry. SLPB numbers correlate with disease activity and anti-dsDNA autoantibody levels in SLE. 39, 40 The circulating SLPB count seems to be an additional biomarker of disease activity. As these newly generated plasmablasts arise from B cell activation and differentiation, they characterize B cell hyperactivity. Consequently, they can be considered an interesting biomarker for selecting patients for B cell targeted therapies with drugs such as belimumab or rituximab. Belimumab not only reduces the numbers of circulating naı¨ve B cells and plasmablasts, but also decreases the ELISA levels of circulating anti-dsDNA autoantibodies. 41 Conversely, it can be speculated that these therapies will not be effective in patients who have persistent anti-dsDNA antibody levels without signs of B cell hyperactivity, as reflected by normal numbers of circulating plasmablasts. Therapies targeting long-lived plasma cells might be the better choice in these cases. Unfortunately, it is challenging to develop strategies for targeting long-lived autoreactive plasma cells. The only available approaches so far are experimental approaches, such as antithymocyte globulin in combination with autologous stem cell transplantation or proteasome inhibitors. 37, 42 In summary, circulating plasmablasts and changes in autoantibody levels might help to select patients who will respond to therapeutic approaches targeting B cells or long-lived memory plasma cells. Systematic studies addressing these issues are needed for this purpose.
Complement components
A large number of complement components exists. Of these, C3, C4, C1q and C5, as well as CH50 (total haemolytic complement activity), are most commonly assessed in clinical practice.
Rarely, primary complement deficiencies of C1q, C1s, C1r, C2 and/or C4, etc., can lead to an increased susceptibility to SLE. 43 Deposits of complement components have also been identified on reticulocytes, erythrocytes and lymphocytes in SLE patients by flow cytometry. In a longitudinal study, erythrocyte-bound C3 and C4 performed comparable to serum C3 and C4. 44 The fact that measuring erythrocyte-bound C3 and C4 provides little additional clinical information and requires flow cytometry might be factors hampering the broader use of these interesting biomarkers.
It is important to note that a change or decrease in serum complement levels is not specific for either diagnosis or disease activity in SLE, because low complement components are also found in other immune complex-mediated diseases. As they are also acute-phase reactants, an increase in complement component levels can also be observed during bacterial infections, which can impair comparability in follow-up.
Most impressively, the levels of complement components can drop sharply, down to even undetectable levels, in patients with active lupus nephritis or haematological manifestations and in the early untreated stages of SLE. 45 In general, complement components can be helpful for assessing overall activity. Abnormally decreased C3 and C4 levels are found in roughly 60% and 50% of patients with severe active lupus, respectively. 29 Large fluctuations in C3 levels might occur without significant clinical implications (Rose et al., submitted) . A certain threshold for a decrease in complement levels over time that might indicate a lupus flare does not yet exist. In some studies, 25% reduction was used as the longitudinal threshold, regardless of time between two visits, but this value was defined arbitrary. 46 Clinically inactive SLE patients with low levels of C3, who are often classified as serologically active clinically quiescent (SACQ), have a higher risk of lupus flares than inactive SLE patients with normal complement C3 levels. 47 Low C3 in combination with elevated anti-dsDNA antibody levels is now used as a companion diagnostic, because belimumab has been shown to provide more benefit to patients with Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLE R Biesen et al.
serologically active SLE. 4 New treatment strategies in SLE should, of course, demonstrate effectiveness, as evidenced by the normalization of biomarkers reflecting overall disease activity. 29 
Type I interferon
The role of type I interferon in SLE was first described by Hooks et al. in 1979 , and a revival of interest in this biomarker occurred in the genomic era. 1, 48, 49 Since indirect measurement of IFN-a was found to be more sensitive, 29, 49 it has been the preferred method. Several indirect assessment tools exist; the whole blood interferon signature (WBIFNS) has become the pharmacodynamic standard marker in clinical trials investigating inhibitors of type I IFN. 50 Moreover, a functional IFN assay has been developed which measures IFNinduced transcripts after incubation of a standardized cell line with SLE sera. 51 54 Activation of the type I IFN system occurs in many autoimmune diseases, such as systemic sclerosis, primary Sjo¨gren's syndrome, dermatomyositis and SLE. 55 Therefore, it is reasonable to assume that activation of the type I IFN pathway is nonspecific and cannot be used as a diagnostic biomarker. So far, no studies have investigated the diagnostic power of IFN biomarkers in SLE. The fact that the normal expression of SIGLEC1 in patients with a first diagnosis of SLE or severe active lupus has not been found 29 suggests that it might be possible to rule out SLE in clinically suspicious individuals who do not have an IFN signature.
Clinical associations of type I interferon in SLE are comparable to clinical manifestations of acute viral infections, including blood suppressive effects, joint and muscle pain, headache, pleurisy, fatigue and fever. Thus, neutropenia, lymphopenia and thrombocytopenia have been linked to side effects of interferon therapy in hepatitis C, as well as to increased levels of IFN-a in SLE. 56, 57 Regarding lupus nephritis, the WBIFNS is strongly associated with active lupus nephritis, 58 and a strong correlation between IFN-induced BclGL expression on CD4þ T cells and proteinuria was observed in a Chinese SLE cohort. 59 Furthermore, we and others have observed a close association between elevated IFN biomarkers and neuropsychiatric complaints, 60 provided these are adequately reflected by disease indices.
The WBIFNS correlated with SLE activity in cross-sectional studies, 58 but failed to reflect changes in disease activity over time. 61, 62 Interestingly, this seems to be an exclusive phenomenon of the WBIFNS, since IFN-a, IP-10, CD64 and SIGLEC1 showed a longitudinal correlation over time. 11, 31, 57 The reasons for this discrepancy have not been addressed so far.
In two large and independent studies, IP-10 outperformed C3 and anti-dsDNA antibody levels in monitoring SLE activity. 31, 63 SIGLEC1 and CD64 expression on monocytes also correlated longitudinally with SLE activity. 64 IFN biomarkers have prognostic utility. In particular, IP-10, was shown to be useful in the prediction of lupus flares and renal flares. 31 Moreover, IFN biomarkers could serve as companion diagnostics for stratification of patients for treatment with new IFN-inhibitors like rontalizumab or anifrolumab. In a phase IIb trial, anifrolumab (a monoclonal antibody against the type I IFN receptor) resulted in an impressive reduction of disease activity and serological biomarkers in patients with moderate to severe SLE. This effect was even greater in patients who had a high IFN signature.
IFN biomarkers also seem to be helpful for escalation and/or de-escalation of glucocorticoids and antimalarials -established IFN-inhibitors that have been used to treat SLE patients for decades. 49, 52, 65 
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